Alzheimer tan chanchin lawmawm

Alzheirmer natna enkawlna lamah khawvelin bung thar a kai hmel anga sawi niin kuminah a tum hnih nan damdawi dang he natna tikhawtlai thei chu siamchhuah a ni leh ta a.
Mithiamte chuan heng damdawi te hi lei mai theih turin peih fel a nih tep thu sawiin chu chu tun hma lam zawng chuan ‘thil ni thei lo’ anga ngaih a ni.
Eli Lilly company te chuan an damdawi siam ‘donemab’ in Alzheimer nasa zel tur hmun thuma thena hmun khatin a tikhawmuang thei an ti a.
Mahse, enchhin nana an hman volunteer pakhat chu thluak vung nasa lutuk avangin a thih phah thung.
Donemab hi a hmaa Alzheimer damdawi atana lo pawm tawh khawvel huapa hriat hlawh lecanemab nen a thawh dan a inang a.
An pahnih hian antibodies ve ve niin virus beitu angin an awm a, thluaka thil hnang ban tak beta amyloid tih te thianfai tura siam a ni.
Amyloid te hi brain cell inkar awlah inhawrkhawma awmin chu chu Alzheimer intanna anga ngaih a ni.
“Kum sawm tam enkawlna hmuhchhuah a nih theih nana hmalakna chuan Alzheimer disease chu a thlang danglam mek a ni” tiin Dr Cath Mummery, clinical lead for the cognitive-disorders clinic, UK’s National Hospital for Neurology and Neurosurgery chaun a sawi a.
“Tunah chuan disease siam danglam hunah kan lut tawh a, Alzheimer natna vei te chu palliative leh supportive care ringawt lovin long-term disease management kan pek theih kan beisei tawh a ni,” tiin a sawi.
Eli Lily’s trial te hi a kimchangin tihchhuah a la ni lo chungin thil pawimawh tak tak tarlan a ni a – Zirchianna neihah Alzheimer vei 1,734 hman an ni a, Donanemab chu thluaka thil inhlawmkhawm danglam tak insiam chu a ral hma chu thla tin pek an ni. Alzheimer natna nasa zel tur 29% in a tihniam tih finfiah a ni bawk a. He damdawi pek te chuan ni tin nunphung pangngai tak tunlai thil thleng sawihona neih te leh an tuina lam tihte an kalpui thei bawk a ni.
Mahse, he damdawi la te chuan a side-effect an neih ve tho chu thluak vung a ni thung a. Zirchianna neihah hian brain scan hnuah 1.6% ten thluak vung deuh an nei tih finfiah a ni bawk.
“Donanemab thatna hmuhchhuah chuan min ti lawm hle a, he natna hlauhawm tak enkawl nan hian tha tawk thei turah kan ngai a, chutih rual chuan a nghawng awm thei thilte pawh a awm tho” tiin Eli Lilly group vice-president of neuroscience research and development Dr Mark Mintun chuan a sawi.
Company-te chuan an damdawi siam chu thla rei lo te chhungin hospital a hman a nih theihna tura phalna an dil nghal tur thu an sawi bawk a.
Dr Liz Coulthard, University of Bristol chuan ‘side-effect a nei chungin’ he damdawi hian Alzheimer natna veite chu a tanpui nasa dawn a ni tiin a sawi.
Hei mai bakah hian scientists te chuan thluaka amyloid bitum chuan danglamna a siam tih an finfiah tawh avangin kum sawm tam tak chhung an lo hlawhchham tawhnaah phurna thar an neih thu an sawi bawk a.
“Tunah chuan amyloid chungchangah rinhlelhna kan nei tawh lovang,” tiin Prof John Hardy, UK Dementia Rsearch Institute a thawk kum 30 kaltaa a hnathawh avanga amyloid bik bitum phahna chuan a sawi a, “Damdawi pahnih neih tawh ringawt pawh hian inelna a siam dawn a ni,” tiin a sawi.
Dr Susan Kolhaas, Alzheimer’s Research UK chuan, “Tunah chuan Alzheimer disease enkawlna tur first generation kan nei thei dawn ta a, kum sawm kalta kha chuan thil theih loh anga ngaih a ni,” tiin a sawi.
Mahse, he damdawi hi Alzheimer vei tan tirteah chauh a thawk nia ngaih niin thluak a tihchhiat tam lutuk hma dinhmuna dingah te chauh a thawk rih nia ngaih a ni.
Thuneituten an pawm a nih chuan Alzheimer vei leh vei loh finfiahna lama bungthar siamtu tur a ni hrim hrim a. Tun dinhmunah mipui 1-2% te chauhin brain scan neiin spinal-fluid analysis hmachhawna Alzheimer an vei leh vei loh infiah tum an awm chauh rih tia sawi a ni.
Chumi piah lamah chuan NHS te chuan mipui nawlpuiin an lei phak dawn em tih chu an la tihchian ngai a ni a, Lecanemab manah mi pakhatin kum khatah a tlem berah 21,000 pound a sen ngei ngei a ngai a ni.